independence blue cross glp 1 coverage Why we are changing of GLP-1 drugs for weight loss Insurance coverage just changed for

Clinical trials conducted on Wegovy patients revealed that approximately 44 percent reported nausea, while almost 25 percent reported vomiting, both of which are common symptoms of gastroparesis

Soc Open Sci

The peptides selective action allows for targeted fat reduction without the hormonal trade-offs that typically complicate weight management

Under ad libitum feeding conditions, we found that heart, body, and heart/body weights and nonfasting tail blood glucose measurements were not affected by treatment assignment (Supplemental Figure 1

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes . Journal of the American Heart Association , 2024